Parathyromatosis and the Challenge of Treatment

American Journal of Kidney Diseases

Volumn 48, Issue 3, 2006, Pages 502-505

  Daphnis, Eugene ^a   Stylianou, Kostas ^a   Katsipi, Irene ^a   Stratigis, Spyros ^a   Karamitopoulou, Eva ^a   Karkavitsas, Nikolaos ^a   Kyriazis, John ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

bisphosphonates; calcimimetics; hypercalcemia; Parathyromatosis; paricalcitol; secondary hyperparathyroidism

Indexed keywords

CALCIMIMETIC AGENT; CALCITRIOL; CINACALCET; IBANDRONIC ACID; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PARATHYROID HORMONE; PARICALCITOL; VITAMIN D DERIVATIVE;

ADULT; ARTICLE; CASE REPORT; DISEASE COURSE; FEMALE; HISTOLOGY; HORMONE RELEASE; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; IMAGING; KIDNEY DISEASE; MORBIDITY; PARATHYROID DISEASE; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID SCINTISCANNING; PARATHYROIDECTOMY; PARATHYROMATOSIS; RECURRENT DISEASE; SUBTOTAL THYROIDECTOMY;

ADULT; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DISEASE PROGRESSION; ERGOCALCIFEROLS; FEMALE; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; REOPERATION;

EID: 33747600893     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2006.05.010     Document Type: Article

References (25)

1. Palmer J.A., Brown W.A., Kerr W.H., Rosen I.B., and Watters N.A. The surgical aspects of hyperparathyroidism. Arch Surg 110 (1975) 1004-1007
2. Reddick R.L., Costa J.C., and Marx S.J. Parathyroid hyperplasia and parathyromatosis. Lancet 1 (1977) 549
3. Rattner D.W., Marrone G.C., Kasdon E., and Silen W. Recurrent hyperparathyroidism due to implantation of parathyroid tissue. Am J Surg 149 (1985) 745-748
4. Evans C.F., Mansfield L., and Sharma A.K. Recurrent hyperparathyroidism caused by parathyromatosis. Hosp Med 66 (2005) 424-425
5. Falvo L., Catania A., Sorrenti S., D'Andrea V., Santulli M., and De Antoni E. Relapsing secondary hyperparathyroidism due to multiple nodular formations after total parathyroidectomy with autograft. Am Surg 69 (2003) 998-1002
6. Lentsch E.J., Withrow K.P., Ackermann D., and Bumpous J.M. Parathyromatosis and recurrent hyperparathyroidism. Arch Otolaryngol Head Neck Surg 129 (2003) 894-896
7. Makela S., Saha H., Helin H., Sand J., and Pasternack A. Uncontrollable hypercalcemia in a dialysis patient-Parathyromatosis or parathyroid carcinoma?. Duodecim 117 (2001) 183-186
8. Baloch Z.W., Fraker D., and LiVolsi V.A. Parathyromatosis as cause of recurrent secondary hyperparathyroidism. A cytologic diagnosis. Diagn Cytopathol 25 (2001) 403-405
9. Lee P.C., Mateo R.B., Clarke M.R., Brown M.L., and Carty S.E. Parathyromatosis. A cause for recurrent hyperparathyroidism. Endocr Pract 7 (2001) 189-192
10. Stehman-Breen C., Muirhead N., Thorning D., and Sherrard D. Secondary hyperparathyroidism complicated by parathyromatosis. Am J Kidney Dis 28 (1996) 502-507
11. Kollmorgen C.F., Aust M.R., Ferreiro J.A., McCarthy J.T., and van Heerden J.A. Parathyromatosis. A rare yet important cause of persistent or recurrent hyperparathyroidism. Surgery 116 (1994) 111-115
12. Fitko R., Roth S.I., Hines J.R., Roxe D.M., and Cahill E. Parathyromatosis in hyperparathyroidism. Hum Pathol 21 (1990) 234-237
13. Meakins J.L., Milne C.A., Hollomby D.J., and Goltzman D. Total parathyroidectomy. Parathyroid hormone levels and supernumerary glands in hemodialysis patients. Clin Invest Med 7 (1989) 21-25
14. Nguyen N.D., Eisman J.A., and Nguyen T.V. Anti-hip fracture efficacy of bisphosphonates. A Bayesian analysis of clinical trials. J Bone Miner Res 21 (2006) 340-349
15. Toregrossa J.V., Moreno A., Mas M., Ybarra J., and Fuster D. Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis. Kidney Int Suppl 85 (2003) S88-S90
16. Bergner R., Dill K., Boerner D., and Uppenkamp M. Elimination of intravenously administered ibandronate in patients on hemodialysis. A monocentre open study. Nephrol Dial Transplant 17 (2002) 1281-1289
17. Nemeth E.F., and Bennett S.A. Tricking the parathyroid gland with novel calcimimetic agents. Nephrol Dial Transplant 13 (1998) 1923-1925
18. Block G.A., Martin K.J., de Francisco A.L., et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350 (2004) 1516-1525
19. Lindberg J.S., Culleton B., Wong G., et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis. A randomized, double-blind, multicenter study. J Am Soc Nephrol 16 (2005) 800-807
20. Lindberg J.S., Moe S.M., Goodman W.G., et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium × phosphorus in secondary hyperparathyroidism. Kidney Int 63 (2003) 248-254
21. Quarles L.D., Sherrard D.J., Adler S., et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14 (2003) 575-583
22. Colloton M., Shatzen E., Miller G., et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 67 (2005) 467-476
23. Cunningham J., Danese M., Olson K., Klassen P., and Chertow G.M. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68 (2005) 1793-1800
24. Moe S.M., Chertow G.M., Coburn J.W., et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCL. Kidney Int 67 (2005) 760-771
25. Moe S.M., Cunningham J., Bommer J., et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCL. Nephrol Dial Transplant 20 (2005) 2186-2193